Predictors of pregnancy in microbicide trials

Contraception

Volumn 83, Issue 5, 2011, Pages 436-440

  Halpern, Vera ^a   Lie, Che Chin ^a   Feldblum, Paul ^a   Van Damme, Lut ^a,b   Weaver, Mark ^a   Mauck, Christine ^b   Guédou, Fernand ^c   Mirembe, Florence ^d   Govinden, Roshini ^e   Obunge, Orikomaba ^f   Ogunsola, Folasade ^g  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d MAKERERE UNIVERSITY   (Uganda)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^f UNIVERSITY OF PORT HARCOURT   (Nigeria)

^g UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Contraception; HIV prevention trials; Microbicide; Pregnancy; Risk factors

Indexed keywords

C31G; CELLULOSE SULFATE; INJECTABLE CONTRACEPTIVE AGENT; MICROBICIDE; ORAL CONTRACEPTIVE AGENT; SAVVY; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CONDOM; CONTRACEPTIVE DEVICE; EDUCATIONAL STATUS; FEMALE; FEMALE STERILIZATION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MARRIAGE; MEDICAL HISTORY; ORAL CONTRACEPTION; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PREGNANCY RATE; RISK ASSESSMENT; RISK FACTOR; SAFE SEX; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; VAGINAL DELIVERY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CONTRACEPTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 79954425007     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.08.018     Document Type: Article

References (13)

1. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007;370:251-61. (Pubitemid 47069513)
2. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY Vaginal Gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008;3:e1474.
3. Raymond EG, Taylor D, Cates Jr W, et al. Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis 2007;34:1035-9. (Pubitemid 350158859)
4. Institute of Medicine of the National Academies. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press; 2008.
5. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005;21:845-53.
6. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE 2008;3:e3784.
7. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72.
8. Therneau TM, Grambsch PM. Modeling Survival Data. New York: Springer; 2000.
9. Kost K, Singha S, Vaughana B, Trussell J, Bankolea A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008;77:10-21.
10. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008;371:2183-91. (Pubitemid 351885039)
11. Raymond EG, Chen PL, Pierre-Louis B, et al. Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness. BMC Med Res Methodol 2004;4:23.
12. Holt BY, Kilbourne-Brook M, Stone A, et al. Multipurpose prevention technologies for sexual and reproductive health: gaining momentum and promise. Contraception 2010;81:177-80.
13. Feldblum PJ, Nasution MD, Hoke TH, et al. Pregnancy among sex workers participating in a condom intervention trial highlights the need for dual protection. Contraception 2007;76:105-10. (Pubitemid 47080984)